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Abstract 
 
Introduction: Women attending breast screening may have suspicious mammographic findings that 
are subsequently found at assessment clinic to be normal (false positive, FP). A false positive 
diagnosis is not harmless, with short and long term negative psychosocial consequences reported. 
Women are at increased relative risk of breast cancer therefore their attendance at subsequent 
screening is essential. 
 
Aims: To assess the impact of FP breast screening diagnosis and diagnostic work-up on re-
attendance rates across four consecutive screening rounds at a typical breast screening centre.  
 
Method: Diagnostic interventions and screening re-attendance rates at one prior and two consecutive 
rounds were analysed for women receiving a FP diagnosis between 2004-2006.  
 
Results: 397 women (5.57%) were referred for further assessment, including 228 (57.43%) false 
positives. 34 eligible women failed to re-attend routine screening (+ 3 years), with 17 failing to re-
attend subsequently (+ 6 years). 70.6% (24/34) of non-attenders had attended at least two screening 
rounds prior to FP assessment. 75% of FP women had an imaging-only assessment with 17.5% 
(30/171) failing to re-attend, and 25% received a biopsy, with 7% (4/57) failing to re-attend 
subsequently.   
 
Conclusion: This study is unique as it follows FP women through four consecutive screening rounds. 
FP non-attendance rates were considerably lower compared to the general screening population, with 
diagnostic work-up having limited influence. FP non-attendance may appear insignificant in 
comparison to total screened population, but these women are at greater risk of subsequent cancer 
so should be actively encouraged to re-engage with the screening programme.    
 
 
Introduction 
 
Breast cancer is the most common cancer in the UK, with a 1 in 8 lifetime risk of women developing 
the disease [1]. If breast cancer can be found at an early stage, prognosis is improved, and therefore 
eligible women in a range of countries are invited to have a mammogram examination within a breast 
screening programme every 1-3 years. In 2012 the NHS Breast Screening Programme extended the 
age range of women eligible for 3-yearly breast screening from 47 to 73 years [2].  
 
5-9% of women attending routine mammography will have suspicious findings on their mammogram 
[3], necessitating referral to a breast cancer assessment clinic for further investigation. Following 
further assessment a significant proportion of these women will be given a ‘normal’ or ‘benign’ result, 
with no requirement for further treatment. This is considered to be a false positive (FP) result, with 
subsequent referral back into the screening programme (known as routine recall). A retrospective 
cohort study of 140,387 women identified that false positive women are at greater risk of cancer being 
detected at the next screen, interval cancer (cancers becoming symptomatic between the screening 
rounds), and larger cancers at presentation [3]. Von Euler-chelpin et al also identified an increased 
relative risk of breast cancer after a false-positive test which remained statistically significantly 
increased six or more years later, although technological improvements have reduced the size of 
excess risks [4]. Nonetheless both authors stress that it is essential that all false positive women are 
encouraged to re-attend for their next routine appointment. 
 
A systematic review and meta-analysis by Brewer et al of over 340,000 attendances [5], later updated 
by Salz [6], identified that, within Europe, FP women are just as likely to re-attend routine screening 3 
years later as those who had a ‘normal’ mammogram result. FP women in the USA are more likely to 
re-engage with the screening programme, and women in Canada less likely to re-engage [5.6]. Such 
differences are likely to reflect the variation in design of screening programmes and intervals, as well 
as differences in access to health care. While attendance at an assessment clinic is not the only 
factor to influence a woman’s decision to participate in subsequent screening, a systematic review  
has demonstrated that the assessment clinic experience is intensely stressful, with increases in 
anxiety, worry and intrusive thoughts occurring in the short and medium term [7]. A more recent study 
[8] agreed that there were medium term (6 months) negative effects experienced by false positive 
women that were experienced at a similar level to women who had received a diagnosis of cancer. 
However when evaluated at three years after being declared free of cancer, these FP women still 
reported greater negative psychosocial consequences compared to women with normal screening 
findings [8]. This three year timeframe coincides with an invitation for the next routine screen within 
the UK – just receiving such an invitation has been shown to increase negative thoughts [9].   
While some published literature suggests that the degree of diagnostic workup within an assessment 
clinic does not influence re-attendance rates [10], the Irish breast screening programme has identified 
that the more invasive the test, the less likely the client is to re-attend for subsequent screening [11].  
The degree of diagnostic work-up may significantly affect the experience of the client and the nature 
of the staff-client interactions [12], with potential for anxious clients to receive information overload, 
insufficient information or even conflicting information.  
This study aimed to identify the potential links between false positive diagnoses and diagnostic work-
up on breast screening re-attendance rates at a typical breast screening unit in England. While 
previous studies have followed FP women for one screening round (3 years), this study aimed to 
correlate attendance both three years before the FP diagnosis, and then at two subsequent screening 
rounds (3 years and 6 years post FP diagnosis). The study received both ethical approval 
[11/NW/0741] and local R+D approval.    
 
Methodology 
 
The screening re-attendance rates for false positive (FP) women attending a typical breast screening 
unit over a 3 year period (2004-2006) were analysed via a retrospective study. This period was 
selected for data collection to enable follow up of these women through two further screening rounds 
(additional 6 years) with the later women being invited to their second screen in 2012. All women 
called back to assessment following routine screening attendance were reviewed. Those women who 
went on to be referred to a breast surgeon for further investigations and treatment were discounted 
and only those who were referred back to routine screening (FP) were considered further. 
 
For all eligible FP women attending an assessment clinic (2004-2006), the diagnostic tests that they 
underwent were noted and correlated with subsequent screening attendance. Diagnostic tests 
received within the assessment clinic visit were categorised as either imging-only (mammograms and 
ultrasound) or biopsies.  
The audit data was collated into the following categories: 
a) Number of women referred to assessment clinic between 1
st
 April 2004 and 31
st
 March 
2007 
b) Number of women designated as ‘normal’ following assessment (FP) 
c) Assessment clinic interventions received by FP women  
d) Number of eligible women who returned for subsequent routine screening three years 
later and of those women failing to re-attend the number who returned for routine 
screening six years later 
e) Number of FP women failing to re-attend 3 years later who had previously attended for 
breast screening before their false positive assessment  
 
 
 
Results 
Following invitations to attend a breast screening appointment, the attendance rates at the study 
centre were 70.2% (2007); 72.67% (2008); 70.93% (2009). The breast screening unit screened a total 
of 7124 women during the 3 year period.  
The audit considered women called back to assessment in 2004-6 and the subsequent screening re-
attendance in 2007-9 and again in 2010-12. 397 women were referred for further assessment, 
equating to an overall 5.57% assessment referral rate. Within the three year period (2004-6), a total of 
228 women (57.43%) who had been referred for further assessment were subsequently referred back 
to routine recall. These women were categorised as False Positive (FP) results (see Table 1).  
The 228 FP women were tracked to identify subsequent re-engagement with routine screening 
mammography three years later. In total 25.89% (n=59) of false positive women failed to re-attend 
their subsequent screening round in 2007-9. It should be noted, however, that not all the women with 
false positive results, were eligible for subsequent routine recall for various reasons including being 
under consultant care (n=5), over 70 years of age (n=19) or moved away from the screening area 
(n=1). 
Of those women eligible for subsequent screening 14.91% (n=34) did not re-attend the following (+ 3 
years) screening round. Of these 34 women, 79.41% (n=27) did not attend for screening six years 
later. It should again be noted, however, that not all women were eligible for subsequent routine recall 
for various reasons including deceased (n=3), under consultant care (n=2), over 70 years (n=8) and 
moved away from screening area (n=4). See Table 2 and Figure 1.  
 The eligible women who failed to attend for subsequent screening were investigated to identify 
whether they had previously engaged with the screening programme (attending at least one 
screening round prior to their false positive assessment in 2004-6). The majority of the non-attenders 
at subsequent screening (24/34; 70.6%) had attended at least one screening round prior to their false 
positive result. See Table 3. 
75% of the 228 FP women (n=171) had received an imaging-only assessment before being referred 
back to routine screening. 22.81% women (n=52) had received interventions including a stereo taxis 
breast biopsy, and just 2.19% of FP women (n=5) had received an ultrasound breast biopsy before 
being referred back to routine screening (see Table 4). The numbers of eligible women failing to re-
attend were correlated with the type of intervention they had received (Table 5). 17.5% (30/171) of 
women having imaging-only interventions failed to re-attend three years later, while 7% (4/57) of 
women having biopsy interventions (SBB + UBB) failed to re-attend.    
 
 
 
Discussion 
This research centred in a typical breast screening unit has attempted to identify whether women who 
have received a false positive result are more or less likely to attend for subsequent screening. This 
unit is a medium sized screening unit serving a largely socially deprived, mixed ethnicity population in 
the North West of England. In the three year period under observation, 5.57% of women were 
referred for further assessment, which is within recommended referral benchmarks of the NHS Breast 
Screening Programme [13;14].   
Of the 397 women referred for further assessment between the years 2004-6, 57.43% (n=228) 
received a false positive diagnosis and were referred back into the routine screening programme. This 
compares to a recent smaller-scale UK audit (6 month timeframe) with findings of 77.5% [15]. The 
number of referrals to assessment and false positive results appears to be relatively stable over the 
three years in the study centre.   
The audit has identified that over the three year period, 34 (14.91%) false positive eligible women 
failed to re-attend when invited to their subsequent routine screening appointment. This is not 
dissimilar to a previous audit which identified 13% of eligible false positive women not attending for 
subsequent screening [15]. However no national benchmarks exist with which to compare directly the 
‘FP failure to re-attend’ rates in this study. Breast screening population cohorts are fluid and 
inconsistent (older women leaving the programme and young women joining), so the NHSBSP (2010) 
standards focus on attendance rather than re-attendance, requiring attendance rates of more than 
70% [14]. The attendance rates at the study centre comply with these standards for each of the study 
cohorts.  
When comparing the re-attendance rates for the FP women in this study (85.1%) with the attendance 
rates in the general screening population over the same three year period (circa 71%), the FP re-
attendance rates appear favourable. A meta-analysis of over 340,000 attendances [5;6] identified that 
European FP women are just as likely to re-attend routine screening as those who had a ‘normal’ 
mammogram result. The European results were based upon a number of studies in the UK, France, 
Norway and Denmark, which showed significant variation in attendance results per region, with a 
French study reporting an attendance rate consistently under 44% [6]. It is therefore more appropriate 
to compare the results of our study with other UK studies, but many of these studies were published 
at least a decade ago, based upon early screening rounds. Later rounds, such as those on which this 
research is based, may have different characteristics due to increased participant familiarity and 
acceptance of the screening programme, and the effects of increased positive and negative media 
coverage. A small-scale audit demonstrated no significant difference between non-attendance in the 
false positive group and non-attendance in the ‘normal’ screening population [15], but these 
conclusions are similarly flawed as they are not comparing like-for-like study populations.  
Our study is unique in following FP women through two future attendances, as well as one prior 
attendance. 34 FP eligible women failed to attend 3 years later, and 27 of these eligible women failed 
to re-attend 6 years later. The majority of the FP non-attenders (24/34 70.6%) had attended at least 
one screening round prior to their false positive results. This is concerning because these women 
could be considered ‘habitual’ attenders, having attended at least two breast screening rounds. 
Without interrogating these false positive women directly, it is impossible to state that a ‘negative’ 
assessment clinic experience influenced their decision to no longer engage with the screening 
programme, but this must be a consideration. Previous literature has suggested that assessment 
clinic attendance can be a ‘distressing’ experience [7;12], although a recent study on ‘intent to re-
attend’ suggested that a positive assessment clinic experience could improve confidence in the breast 
screening programme [16]. However even three years following FP diagnosis, women are still likely to 
experience greater negative psychosocial consequences than women with a normal diagnosis [8], so 
this heightened anxiety is likely to influence decision-making upon receiving the screening invitation.  
Over a three year period, 34 false positive women failing to re-engage with the screening programme 
does not seem high when one considers the thousands of clients that any one unit engages with in 
any one year. However there is evidence to suggest that these false positive women are at greater 
excess risk of future breast cancer [3;4;11], so it is imperative that all false positive women are 
encouraged by their units to re-attend for their next routine appointment. 
In this study 75% of the false positive women referred to the assessment clinic received an imaging-
only intervention. The numbers referred for breast biopsy are compliant with NHSBSP (2010) 
guidance which states that approximately 1% of women screened will undergo a needle biopsy [14]. 
Those women undergoing breast biopsy procedures in this study were more likely to return to future 
screening than those undergoing minimally invasive assessment (17.5% compared to 7%). While 
caution should be shown because numbers of women in each category are small, this local finding is 
in opposition to the findings of the large-scale Fitzpatrick et al study (biopsy candidates less likely to 
attend) [11] and Signeurin et al (no effect of diagnostic work-up on attendance) [10]. We propose that 
although biopsy procedures are potentially more distressing and require a longer anxious wait for 
results, this delay in receiving results may in fact work in the woman’s favour, offering them more time 
to consider their situation, seek support from family members, and ask pertinent questions of health 
care staff at their follow-up visit one week later. This ‘continuum of care’ may leave women with a 
positive perception of the breast screening unit.  
 
 Conclusion 
In this study, the re-attendance rates for the FP women are considerably higher than attendance rates 
in the general screening population over the same three year period, though this is not a like-for-like 
comparison. The percentage of false positive women failing to re-attend for subsequent screening 
was similar to other published literature. The majority of the eligible women failing to re-attend for 
subsequent screening had previously engaged well with the screening programme. Even though ‘FP 
failure to re-attend’ numbers form a very small proportion of the screening population, it is imperative 
for screening units to understand their own local situation, because false positive women are known 
to be in a higher risk group for cancer and re-engagement with the screening programme is vital.  
While actual numbers were too small to make definite conclusions, the degree of diagnostic work-up 
did have some influence on re-attendance rates, with women receiving biopsies more likely to re-
attend for subsequent screening. It is possible that the higher level of communication and the longer 
continuum of care afforded to these women has some beneficial effects regarding their perception of 
the wider breast screening programme. The authors hypothesise that this continuing care model 
would be beneficial for all clients attending the assessment clinic, regardless of diagnostic work-up, 
and further qualitative research is underway at the study centre to identify whether a continuum of 
care could be afforded by an enhanced radiographer role.  
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Figure 1 Chart demonstrating the numbers of false positive women who failed to re-attend at 3 
years and 6 years. 
 
 
 
Table 1 Screening Unit Activity: Number of women screened, referred for assessment and 
subsequently categorised as false positive 
  
 
2004 2005 2006 Total 
No. women screened annually 
 
2595 2266 2263 7124 
No. screened women referred 
for further assessment 115 145 137 397 
Assessment referral rate (%) 4.43 6.40 6.05 
 
5.57 
No. women with a false 
positive diagnosis 69 70 89 228 
Percentage (%) of assessed 
women classified false positive 60.00 48.28 64.96 57.43 
 
Table 2 Number of eligible false positive women failing to re-attend after 3 years and after 6 
years 
  
 
2007 2008 2009 Total 
No. FP women failing to attend (+ 3 years) 
 
11 14 9 34 
Non-attendance (%)(+ 3 years) 
 
15.94 20.00 10.11 14.91 
Attendance (%) (+3 years) 
 
84.06 80.00 89.89 85.09 
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Year 
False positive after
further assessment
Failed to reattend after 3
years
Failure to re-attend after
6 years
No. FP women failing to attend at 2 subsequent 
screening rounds (+ 3 and +6 years) 11 9 7 27 
Percentage women not attending at +3 years also 
not attending at 6 years (%) 100.00 64.29 77.78 79.41 
 
 
Table 3 Previous attendance history of false positive women who failed to re-attend at 3 years 
  
 
2004 2005 2006 Total 
No. False Positive women 
 
69 70 89 228 
No. FP women who did not attend after 3 
years 11 14 9 34 
No. FP women not attending at 3 years who 
had previously attended at least one round 9 11 4 24 
Percentage who had previously attended 
 
81.82 78.57 44.44 70.59 
 
Table 4 Interventions received by false positive women 
  2004 2005 2006 Total 
mammography targeted projections or 
ultrasound (imaging only) 44 55 72 171 
Imaging only % 63.77 78.57 80.90 75.00 
stereo taxis breast biopsy (SBB) 22 10 20 52 
SBB % 31.88 14.29 22.47 22.81 
ultrasound breast biopsy (UBB) 2 0 3 5 
UBB % 2.90 0.00 3.37 2.19 
 
Table 5 Assessment clinic interventions received by subsequent FP non-attenders 
  2004 2005 2006 Total 
mammography targeted projections or 
ultrasound (imaging-only) 
44 55 72 171 
Number of non-re-attendance after 3 years 
(imaging-only) 
7 14 9 30 
Percentage of non-re-attendance after 3 years 
(imaging-only) 
15.91 25.45 12.50 17.54 
stereo taxis breast biopsy (SBB) 22 10 20 52 
Number of non-re-attendance after 3 years 
(SBB) 
4 0 0 4 
Percentage of non-re-attendance after 3 years 
(SBB) 
18.18 0.00 0.00 7.69 
ultrasound breast biopsy (UBB) 2 0 3 5 
Number of non-re-attendance after 3 years 
(UBB) 
0 0 0 0 
Percentage of non-re-attendance after 3 years 
(UBB) 
0.00 0.00 0.00 0.00 
 
 
